These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18566686)

  • 1. PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate.
    Glazer RI; Yuan H; Xie Z; Yin Y
    PPAR Res; 2008; 2008():247379. PubMed ID: 18566686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
    Berger J; Leibowitz MD; Doebber TW; Elbrecht A; Zhang B; Zhou G; Biswas C; Cullinan CA; Hayes NS; Li Y; Tanen M; Ventre J; Wu MS; Berger GD; Mosley R; Marquis R; Santini C; Sahoo SP; Tolman RL; Smith RG; Moller DE
    J Biol Chem; 1999 Mar; 274(10):6718-25. PubMed ID: 10037770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer.
    Glazer RI; Kopelovich L
    Oncotarget; 2017 Aug; 8(31):50337-50341. PubMed ID: 28881566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages.
    Hall JM; McDonnell DP
    Mol Endocrinol; 2007 Aug; 21(8):1756-68. PubMed ID: 17488971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages.
    Vosper H; Patel L; Graham TL; Khoudoli GA; Hill A; Macphee CH; Pinto I; Smith SA; Suckling KE; Wolf CR; Palmer CN
    J Biol Chem; 2001 Nov; 276(47):44258-65. PubMed ID: 11557774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and Challenges in Drug Design of PPARδ Ligands.
    Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
    Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation.
    Wagner KD; Benchetrit M; Bianchini L; Michiels JF; Wagner N
    J Pathol; 2011 Aug; 224(4):575-88. PubMed ID: 21598253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic expression of porcine peroxisome proliferator-activated receptor delta regulates adipogenesis in mouse myoblasts.
    Yu YH; Wu SC; Cheng WT; Mersmann HJ; Ding ST
    J Anim Sci; 2008 Jan; 86(1):64-72. PubMed ID: 17878286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease and PPARdelta: targeting the risk factors.
    Muscat GE; Dressel U
    Curr Opin Investig Drugs; 2005 Sep; 6(9):887-94. PubMed ID: 16187688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARδ, PPARγ, and RXR.
    Li JE; Futawaka K; Yamamoto H; Kasahara M; Tagami T; Liu TH; Moriyama K
    Am J Chin Med; 2015; 43(5):879-92. PubMed ID: 26227398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis.
    Panigrahy D; Huang S; Kieran MW; Kaipainen A
    Cancer Biol Ther; 2005 Jul; 4(7):687-93. PubMed ID: 16082179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.
    Kopelovich L; Fay JR; Glazer RI; Crowell JA
    Mol Cancer Ther; 2002 Mar; 1(5):357-63. PubMed ID: 12489852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.
    Welch JS; Ricote M; Akiyama TE; Gonzalez FJ; Glass CK
    Proc Natl Acad Sci U S A; 2003 May; 100(11):6712-7. PubMed ID: 12740443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
    Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
    Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
    Hummasti S; Tontonoz P
    Mol Endocrinol; 2006 Jun; 20(6):1261-75. PubMed ID: 16556736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of PPARs in Cancer.
    Tachibana K; Yamasaki D; Ishimoto K; Doi T
    PPAR Res; 2008; 2008():102737. PubMed ID: 18584037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.